Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ly-2090314. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B known ✓ | P49841 | 20/20 | 0.92 |
| ▸ | GSK3A known ✓ | P49840 | 14/20 | 0.92 |
| ▸ | PRKCB | P05771 | 6/20 | 0.92 |
| ▸ | CDK4 | P11802 | 6/20 | 0.92 |
| ▸ | CDK2 | P24941 | 5/20 | 0.92 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.92 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.92 |
| ▸ | CAMK2G | Q13555 | 3/20 | 0.92 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.92 |
| ▸ | PRKCG | P05129 | 2/20 | 0.92 |
| ▸ | LCK | P06239 | 2/20 | 0.92 |
| ▸ | CDK1 | P06493 | 2/20 | 0.92 |
| ▸ | PIM1 | P11309 | 2/20 | 0.92 |
| ▸ | CLK2 | P49760 | 2/20 | 0.92 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.92 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.92 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.92 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.92 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.92 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ly-2090314 SCHEMBL29533963 | 0.96 | GSK3B (1.00) | GSK3BGSK3APRKCBCDK4CDK2 | |
| Ly-2090314 SCHEMBL633455 | 0.96 | GSK3B (1.00) | GSK3BGSK3APRKCBCDK4CDK2 | |
| Ly-2090314 SCHEMBL635424 | 0.95 | GSK3B (0.98) | GSK3BGSK3APRKCBCDK4CDK2 | |
| Ly-2090314 SCHEMBL633612 | 0.94 | GSK3B (0.93) | GSK3BGSK3APRKCBCDK4CDK2 | |
| SCHEMBL23874280 | 0.90 | GSK3B (0.89) | GSK3BGSK3APRKCBCDK4CDK2 | |
| SCHEMBL21577647 | 0.89 | GSK3B (0.86) | GSK3BGSK3APRKCBCDK4CDK2 | |
| SCHEMBL21577652 | 0.88 | GSK3B (0.81) | GSK3BGSK3APRKCBCDK4CDK2 | |
| Ly-2090314 SCHEMBL29549862 | 0.88 | GSK3B (0.85) | GSK3BGSK3APRKCBCDK4CDK2 | |
| SCHEMBL21577683 | 0.88 | GSK3B (0.84) | GSK3BGSK3APRKCBCDK4CDK2 | |
| SCHEMBL21577649 | 0.88 | GSK3B (0.84) | GSK3BGSK3APRKCBCDK4CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2173348-B1 | POTENTIATION OF CANCER CHEMOTHERAPY | LILLY CO ELI (US) | 2015-12-09 | — | — | EP | disclosed |
| US-9044487-B2 | Hematopoietic neoplasm chemotherapy | ELI LILLY AND COMPANY (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140235621-A1 | HEMATOPOIETIC NEOPLASM CHEMOTHERAPY | ELI LILLY AND COMPANY (US) | 2014-08-21 | — | — | US | disclosed |
| US-8802668-B2 | Hematopoietic neoplasm chemotherapy | ELI LILLY AND COMPANY (US) | 2014-08-12 | — | — | US | disclosed |
| US-8648063-B2 | Potentiation of cancer chemotherapy by 7-(2, 5-dihydro-4-imidazo [1, 2-a] pyridine-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-9-fluoro-1,2,3,4 tetrahydro -2-(1-piperidinyl-carbonyl)-pyrrolo [3,2,1-jk] [1,4] benzodiazepine | ELI LILLY AND COMPANY (US) | 2014-02-11 | — | — | US | disclosed |
| US-20130039996-A1 | POTENTIATION OF CANCER CHEMOTHERAPY BY 7-(2, 5- DIHYDRO- 4-IMIDAZO [1, 2-A] PYRIDINE-3-YL-2,5-DIOXO-IH-PYRROL-3-YL)-9-FLUORO-1,2,3,4 TETRAHYDRO -2-(1-PIPERIDINYL-CARBONYL)-PYRROLO [3,2,1-JK] [1,4] BENZODIAZEPINE | ELI LILLY AND COMPANY (US) | 2013-02-14 | — | — | US | disclosed |
| US-8318713-B2 | Potentiation of cancer chemotherapy by 7-(2, 5-dihydro-4-imidazo [1, 2-A] pyridine-3-yl-2,5-Dioxo-1H-pyrrol-3-yl)-9-fluoro-1,2,3,4 tetrahydro-2-(1-piperidinyl-carbonyl)-pyrrolo [3,2,1-jk] [1,4] benzodiazepine | ELI LILLY AND COMPANY (US) | 2012-11-27 | — | — | US | disclosed |
| EP-2419106-A1 | BENZODIAZEPINE DERIVATIVE FOR THE TREATMENT OF HEMATOPOIETIC NEOPLASM AND LEUKEMIA | Eli Lilly and Company (US) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010120614-A1 | BENZODIAZEPINE DERIVATIVE FOR THE TREATMENT OF HEMATOPOIETIC NEOPLASM AND LEUKEMIA | ELI LILLY AND COMPANY (US) | 2010-10-21 | — | — | WO | disclosed |
| US-20100261712-A1 | HEMATOPOIETIC NEOPLASM CHEMOTHERAPY | ELI LILLY AND COMPANY (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100166884-A1 | POTENTIATION OF CANCER CHEMOTHERAPY BY 7-(2, 5- DIHYDRO- 4-IMIDAZO [1, 2-A] PYRIDINE-3-YL-2,5-DIOXO-IH-PYRROL-3-YL)-9-FLUORO-1,2,3,4 TETRAHYDRO -2-(1-PIPERIDINYL-CARBONYL)-PYRROLO [3,2,1-JK] [1,4] BENZODIAZEPINE | ELI LILLY AND COMPANY | 2010-07-01 | — | — | US | disclosed |
| EP-2173348-A2 | POTENTIATION OF CANCER CHEMOTHERAPY | Eli Lilly & Company (US) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009006043-A2 | POTENTIATION OF CANCER CHEMOTHERAPY BY 7-(2,5-DIHYDRO-4-IMIDAZO [1,2-A]PYRINE-3-YL-2,5-DIOXO-IH-PYRROL-3-YL)-9-FLUORO-1,2,3,4 TETRAHYDRO-2-(1-PIPERIDINYL-CARBONYD-PYRROLO[3,2,1-JK][1,4]BENZODIAZEPINE | ELI LILLY AND COMPANY (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261712-A1 | HEMATOPOIETIC NEOPLASM CHEMOTHERAPY | MLLT1, BCR, MLLT3 | GSK3B 3574/4885GSK3A 3316/4885PRKCB 2013/4885 |
| US-20130039996-A1 | POTENTIATION OF CANCER CHEMOTHERAPY BY 7-(2, 5- DIHYDRO- 4-IMIDAZO [1, 2-A] PYRIDINE-3-YL-2,5-DIOXO-IH-PYRROL-3-YL)-9-FLUORO-1,2,3,4 TETRAHYDRO -2-(1-PIPERIDINYL-CARBONYL)-PYRROLO [3,2,1-JK] [1,4] BENZODIAZEPINE | GRIK1, DCK, HYPK | GSK3B 1540/4885GSK3A 1516/4885PRKCB 1705/4885 |
| US-20100166884-A1 | POTENTIATION OF CANCER CHEMOTHERAPY BY 7-(2, 5- DIHYDRO- 4-IMIDAZO [1, 2-A] PYRIDINE-3-YL-2,5-DIOXO-IH-PYRROL-3-YL)-9-FLUORO-1,2,3,4 TETRAHYDRO -2-(1-PIPERIDINYL-CARBONYL)-PYRROLO [3,2,1-JK] [1,4] BENZODIAZEPINE | HYPK, DCK, GRIK1 | GSK3B 1712/4885GSK3A 1710/4885PRKCB 1578/4885 |
| US-20140235621-A1 | HEMATOPOIETIC NEOPLASM CHEMOTHERAPY | MLLT1, BCR, MLLT3 | GSK3B 3574/4885GSK3A 3316/4885PRKCB 2013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.